Albert Labs International Corp.
Albert Labs International Corp.
Albert Labs International Corp. is a clinical research and laboratory-based drug development company serving the needs of mental health care. Through a succinct, real-world evidence (RWE)-driven clinical journey, Albert Labs seeks to commercialize its psychedelic-based treatments and, in doing so, bring psychedelic-assisted psychotherapy to patients sooner. Focused on accelerating access and faster approvals, Albert Labs prioritizes patients with urgent and unmet needs by developing licensed drugs to treat a variety of mental health conditions. Cancer-related distress, an original goal of Albert Labs' development program, is thought to affect more than 16 million patients worldwide.
Albert Labs International Corp. (ABRT)
SEDAR Information
Information d'entreprise
Capitalisation
Communiqués de presse
Albert Labs Granted MCTO
Albert Labs Announces New Director
Bulletins
2024-0717 - Suspensions - ABRT, JUVA, LITE, VSBY, VSBY.WT.B
le 16 juillet/July 2024
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.
